Literature DB >> 18450681

Course of illness after the onset of chronic rejection in lung transplant recipients.

Mi-Kyung Song1, Annette De Vito Dabbs, Sean M Studer, Sarah E Zangle.   

Abstract

BACKGROUND: Despite the overall negative impact of chronic rejection on quality of life and survival after lung transplant, the specific clinical indicators of deterioration have not been identified.
OBJECTIVES: To describe the course of illness after the onset of chronic rejection, including demographic and transplant variables, morbidity, mortality, health resource utilization, and end-of-life care, and to identify clinical indicators of deterioration in health and limited survival after the onset of chronic rejection.
METHODS: The medical records of 311 recipients of lung transplants between 1998 and 2004 were reviewed retrospectively to identify 60 recipients who experienced chronic rejection.
RESULTS: Median survival after chronic rejection was 31.34 months. Time to rejection (mean, 26.05 months; SD, 16.85) was significantly correlated with overall survival without need of a retransplant (r = 0.64; P < .001). The earlier the onset of chronic rejection or the need for oxygen at home, the shorter was the period of survival after chronic rejection and the more frequent were hospital and intensive care unit admissions and prolonged stays. Of the 26 recipients who died, 65% died at the transplant center, and all but 1 died in the intensive care unit; 3 died after multiple attempts of cardiopulmonary resuscitation; life support was ultimately withdrawn in 69%.
CONCLUSIONS: Lung transplant recipients who experience chronic graft rejection have high rates of morbidity, mortality, and health resource utilization; however, the course of illness after chronic rejection is highly variable.

Entities:  

Mesh:

Year:  2008        PMID: 18450681

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  6 in total

1.  Psychiatric Predictors of Long-term Transplant-Related Outcomes in Lung Transplant Recipients.

Authors:  Emily M Rosenberger; Andrea F DiMartini; Annette J DeVito Dabbs; Christian A Bermudez; Joseph M Pilewski; Yoshiya Toyoda; Mary Amanda Dew
Journal:  Transplantation       Date:  2016-01       Impact factor: 4.939

2.  Family caregiver perspectives on symptoms and treatments for patients dying from complications of cystic fibrosis.

Authors:  Elisabeth P Dellon; Mitchell D Shores; Katherine I Nelson; Joanne Wolfe; Terry L Noah; Laura C Hanson
Journal:  J Pain Symptom Manage       Date:  2010-09-17       Impact factor: 3.612

Review 3.  Psychosocial issues facing lung transplant candidates, recipients and family caregivers.

Authors:  Emily M Rosenberger; Mary Amanda Dew; Andrea F DiMartini; Annette J DeVito Dabbs; Roger D Yusen
Journal:  Thorac Surg Clin       Date:  2012-11       Impact factor: 1.750

4.  Lung Transplant Pulmonologists' Views of Specialty Palliative Care for Lung Transplant Recipients.

Authors:  Eric Nolley; Jessica Fleck; Dio Kavalieratos; Mary Amanda Dew; Daniel Dilling; Rebecca Colman; Maria M Crespo; Hiliary Goldberg; Steven Hays; Ramsey Hachem; Erika Lease; James Lee; John Reynolds; Matthew Morrell; Yael Schenker
Journal:  J Palliat Med       Date:  2020-01-02       Impact factor: 2.947

Review 5.  Chronic lung allograft dysfunction after lung transplantation: the moving target.

Authors:  Masaaki Sato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-11-10

6.  A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation.

Authors:  Aldo Iacono; Marniker Wijesinha; Keshava Rajagopal; Natalia Murdock; Irina Timofte; Bartley Griffith; Michael Terrin
Journal:  ERJ Open Res       Date:  2019-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.